RVLP - RVL Pharmaceuticals plc Stock Price, Fair Value and News

Market Closed

RVLP Stock Valuation Analysis

Valuation

Max Portfolio %

RVLP Price Action

RVLP RSI Chart

RVLP Stock Valuation Analysis

Valuation

Max Portfolio %

RVLP Valuation

RVLP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

RVLP Fundamentals

RVLP Revenue

RVLP Earnings

RVLP Profitability

RVLP Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	37.1M	36.9M	0	0
2022	38.0M	34.9M	42.8M	49.7M
2021	25.2M	22.6M	20.1M	17.5M
2020	158.6M	115.0M	71.4M	27.8M
2019	261.0M	246.7M	245.8M	202.2M
2018	250.2M	254.7M	259.2M	263.7M
2017	0	0	0	245.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

CEO	Mr. Brian A. Markison
WEBSITE	rvlpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	125